Katja Margell - Hansa Biopharma Head Communications

All Insiders . Sweden . 
Stock . Hansa Biopharma AB . Stakeholders . Insider . Katja Margell
HNSA Stock  SEK 31.00  0.50  1.59%   

Insider

Katja Margell is Head Communications of Hansa Biopharma AB
Phone46 46 16 56 70
Webhttps://www.hansabiopharma.com

Hansa Biopharma Management Efficiency

The company has return on total asset (ROA) of (0.2718) % which means that it has lost $0.2718 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.8941) %, meaning that it generated substantial loss on money invested by shareholders. Hansa Biopharma's management efficiency ratios could be used to measure how well Hansa Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.
Hansa Biopharma AB has accumulated 783.93 M in total debt with debt to equity ratio (D/E) of 1.6, which is about average as compared to similar companies. Hansa Biopharma AB has a current ratio of 15.14, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Hansa Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Hansa Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hansa Biopharma AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hansa to invest in growth at high rates of return. When we think about Hansa Biopharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Pr MDOncopeptides AB
N/A
Sylvie RyckebuschBioInvent International AB
N/A
Ingrid TeigeBioInvent International AB
N/A
Cecilia HofvanderBioInvent International AB
56
Hanne BakZealand Pharma AS
70
Lani MorvanZealand Pharma AS
N/A
Mattis RantheExpreS2ion Biotech Holding
N/A
Lars PetersenExpreS2ion Biotech Holding
N/A
Kristina LuthmanOncopeptides AB
N/A
Keith AlexanderExpreS2ion Biotech Holding
N/A
RGN MScBioInvent International AB
N/A
Mette ThornExpreS2ion Biotech Holding
N/A
MSc MScOncopeptides AB
53
Bent MScExpreS2ion Biotech Holding
N/A
Christina BredalZealand Pharma AS
38
Linda HolmstromOncopeptides AB
N/A
Ravinder ChahilZealand Pharma AS
N/A
Jakob LicOncopeptides AB
51
Jens MDZealand Pharma AS
N/A
Peter NygrenOncopeptides AB
64
Annika MBAOncopeptides AB
57
Hansa Biopharma AB , a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases. Hansa Biopharma AB was founded in 2001 and is headquartered in Lund, Sweden. Hansa Biopharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 60 people. Hansa Biopharma AB (HNSA) is traded on Stockholm Exchange in Sweden and employs 150 people.

Management Performance

Return On Equity-0.89
Return On Asset-0.27

Hansa Biopharma AB Leadership Team

Elected by the shareholders, the Hansa Biopharma's board of directors comprises two types of representatives: Hansa Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hansa. The board's role is to monitor Hansa Biopharma's management team and ensure that shareholders' interests are well served. Hansa Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hansa Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Henk Troostwijk, Vice President Commercial Operations
Klaus Sindahl, Head Relations
Sren MSc, Pres CEO
Donato Spota, CFO VP
Christian Kjellman, Senior Vice President Research and Development
Lena Winstedt, Vice President Project Management
Katja Margell, Head Communications
EvaMaria Joed, Vice President Finance & Administration
Anne Lanner, VP Officer
Emanuel Bjrne, VP Devel

Hansa Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hansa Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.89
Return On Asset-0.27
Operating Margin(3.80) %
Current Valuation2.17 B
Shares Outstanding52.44 M
Shares Owned By Insiders7.37 %
Shares Owned By Institutions41.33 %
Price To Book7.52 X
Price To Sales17.67 X
Revenue154.53 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Hansa Stock Analysis

When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY